Loomis, Sayles & Company’s Ligand Pharmaceuticals LGND Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $46.7M | Sell |
410,897
-9,937
| -2% | -$1.13M | 0.06% | 109 |
|
|
2025
Q1 | $44.2M | Buy |
420,834
+23,134
| +6% | +$2.43M | 0.06% | 119 |
|
|
2024
Q4 | $42.6M | Buy |
397,700
+24,921
| +7% | +$2.67M | 0.05% | 140 |
|
|
2024
Q3 | $37.3M | Buy |
372,779
+114,436
| +44% | +$11.5M | 0.05% | 163 |
|
|
2024
Q2 | $21.8M | Buy |
+258,343
| New | +$21.8M | 0.03% | 248 |
|
|
2018
Q3 | – | Sell |
-52
| Closed | -$11K | – | 924 |
|
|
2018
Q2 | $11K | Sell |
52
-9
| -15% | -$1.9K | ﹤0.01% | 790 |
|
|
2018
Q1 | $10K | Sell |
61
-217
| -78% | -$35.6K | ﹤0.01% | 804 |
|
|
2017
Q4 | $38K | Buy |
278
+70
| +34% | +$9.57K | ﹤0.01% | 636 |
|
|
2017
Q3 | $28K | Buy |
208
+142
| +215% | +$19.1K | ﹤0.01% | 698 |
|
|
2017
Q2 | $8K | Buy |
+66
| New | +$8K | ﹤0.01% | 814 |
|
|
2017
Q1 | – | Sell |
-109
| Closed | -$11K | – | 999 |
|
|
2016
Q4 | $11K | Hold |
109
| – | – | ﹤0.01% | 831 |
|
|
2016
Q3 | $11K | Hold |
109
| – | – | ﹤0.01% | 752 |
|
|
2016
Q2 | $13K | Sell |
109
-112
| -51% | -$13.4K | ﹤0.01% | 698 |
|
|
2016
Q1 | $24K | Buy |
221
+195
| +750% | +$21.2K | ﹤0.01% | 707 |
|
|
2015
Q4 | $3K | Buy |
+26
| New | +$3K | ﹤0.01% | 963 |
|